Immuneering Corporation (IMRX)


-0.36 (-3.51%)
Symbol IMRX
Price $9.9
Beta 0.000
Volume Avg. 0.08M
Market Cap 289.562M
Shares () -
52 Week Range 3.7-16.167
1y Target Est -
DCF Unlevered IMRX DCF ->
DCF Levered IMRX LDCF ->
ROE -39.67% Strong Sell
ROA -41.28% Strong Sell
Operating Margin -
Debt / Equity 11.39% Neutral
P/E -4.25 Strong Sell
P/B 2.38 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest IMRX news

Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
NASDAQ Global Market

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.